Slingshot members are tracking this event:

Novartis pivotal data for Tafinlar + Mekinist demonstrated a 63 percent overall response rate in treating rare form of lung cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
NVS Community voting in process

Additional Information

Additional Relevant Details
  • The median Duration of Response for BRAF V600E-mutant NSCLC patients treated with Tafinlar + Mekinist combination therapy was 9 months
  • Efficacy analyses also presented for INC280 (capmatinib) in cMET+ NSCLC 
  • Novartis' growing commitment in treating NSCLC supported by data for three distinct targeted therapies
Basel, June 6, 2016 - Novartis today announced new data for multiple investigational and established non-small cell lung cancer (NSCLC) treatments, including results from a pivotal, Phase II study of Tafinlar (dabrafenib) in combination with Mekinist (trametinib) in patients with BRAF V600E-mutation positive (BRAF V600E­+) NSCLC. In the study, patients treated with Tafinlar + Mekinist demonstrated an overall response rate (ORR) of 63% (95% CI, 49%-76%)[1]. Data were presented during an oral session at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) and also published simultaneously in The Lancet Oncology."This study confirms a fourth actionable biomarker in NSCLC - BRAFV600E - after EGFR, ALK and ROS-1," said David Planchard, MD, PhD, Thoracic Oncology Specialist, Cancer Institute Gustave-Roussy, Villejuif, France and trial's principal investigator. "The potential to treat this oncogene gives hope to a very small, underserved patient population."One-to-two percent (1-2%) of patients with NSCLC have a BRAF V600E mutation[2], which is associated with more aggressive tumors and a poorer prognosis, independent of smoking status[3].In this Phase II, multicenter, non-randomized, open-label study (NCT01336634), 57 patients with metastatic NSCLC who had the BRAF V600E mutation and failed at least one line of chemotherapy took 150 mg of Tafinlar twice daily and 2 mg of Mekinist once daily. The primary endpoint of the trial was investigator-assessed ORR, and key secondary endpoints were Duration of Response (DoR) and Progression-Free Survival (PFS). Independent review response rates were consistent with investigator-assessed response[1].The investigator-assessed median DoR and PFS were 9.0 months (95% CI, 6.9 to 18.3) and 9.7 months (95% CI, 6.9 to 19.6), respectively. Thirty-six of 57 patients (63%) demonstrated a clinical response; of these patients, 50% (18 of 36) continued to respond to treatment at the time of analysis. The most common adverse events (incidence >20%) were pyrexia, nausea, vomiting, diarrhea, asthenia, decreased appetite, dry skin, chills, peripheral edema, cough and rash[1]. Four patients (7%) died from fatal adverse events not related to study treatment as assessed by the investigator[1].
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 06, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Lung Cancer, Tafinlar, Mekinist, Nsclc, Inc280, Capmatinib, Braf V600e